Navigation Links
Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
Date:6/28/2010

p us with the future successful development of AEZS-108 in a number of different LHRH expressing cancers."

President and Managing Director of Almac Diagnostics, Professor Paul Harkin , said "We are very pleased to collaborate with Aeterna Zentaris on this exciting project. The plan to develop a companion diagnostic for AEZS-108 shows Aeterna Zentaris's clear commitment to personalized medicine, which will provide this compound with the best opportunity for success "

About AEZS-108

AEZS-108, a doxorubicin LHRH receptor targeted conjugate, is currently in a Phase 2 trial in advanced ovarian and endometrial cancer. Positive final results in ovarian cancer were disclosed at this year's American Society of Clinical Oncology (ASCO) meeting*, while final results in endometrial cancer are expected by year-end. AEZS-108 has been granted orphan-drug designation by the U.S. Food and Drug Administration and has received a positive opinion for Orphan Medicinal Product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of ovarian cancer.

An Investigational New Drug (IND) in the U.S. is in place for the treatment of bladder cancer.

Additional clinical studies in hormone-resistant prostate cancer and other cancer types are being planned. There may be benefits during the regulatory review process from the medical and scientific logic of this personalized treatment approach to patient selection and possibly have value in reimbursement considerations.

    * Asco poster presentation: abstract #5035 entitled,
        "Phase 2 study of AEZS-108, a targeted cytotoxic LHRH analog, in
        patients with LHRH receptor positive platinum resistant ovarian
        cancer.

About Almac


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ... Companies"  to their offering.       ... a challenge in management. With nearly 8 ... seven major markets of the world and ...
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) ... Market by Products, by Testing services - Global Forecast ... The global animal genetics market is estimated to be ... a CAGR of 8-9% during the forecast period of ... driven by increasing animal protein consumption, increasing adoption of ...
(Date:5/28/2015)... 28, 2015 Natera, Inc., a leader ... published in Ultrasound in Obstetrics & Gynecology ... non-invasive prenatal test (NIPT) can identify a complete ... A study based upon data collected in ... in about 1 in 1,000 pregnancies, although other ...
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
Breaking Biology Technology:Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... JOSEPH, Mich., Feb. 5 GeneGo, Inc., the ... has extended their,licensing agreement with GeneGo and have ... Bioinformatics, R&D and clinical studies,with global access to ... for functional analysis of biological OMICs data,featuring a ...
... Forest Laboratories, Inc.,(NYSE: FRX ) ... III study of,memantine HCl (currently marketed as ... novel once-daily formulation. The study evaluated,the efficacy, ... 28 mg,memantine extended-release, once-daily formulation compared to ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a biotechnology Company ... targeting the chronic inflammation,underlying cardiovascular and neurological disease, ... present a Company Overview at BIO,CEO & Investor ... at 11:00,a.m. (ET) on Tuesday, February 12, 2008. ...
Cached Biology Technology:GSK Extends GeneGo License and Adds New Products 2Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 2Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 3Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 4Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Immunogenetics experts at The Children,s Hospital of Philadelphia ... characterize the genes that encode HLA molecules. The ... technology to type human leukocyte antigens (HLAs)--complex, highly ... to immune function. The new test may ...
... will be the subject of a symposium on Saturday, February 15, ... Advancement of Science in Chicago. The session, which features two ... Martin Chalfie, will take place 10:00-11:30 a.m. CST in Grand Ballroom ... the first 2014 winner of the Golden Goose Award ...
... aware of the health benefits of dietary fiber. But what ... Research at the University of Michigan Medical School, the University ... Sweden, has begun to uncover how our gut bacteria metabolize ... Trillions of bacteria live in human intestines - there are ...
Cached Biology News:CHOP introduces HLA typing by next-generation sequencing to its clinical services 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 3U-M scientists & colleagues investigate the fiber of our being 2
... Fiberboard boxes are ideal for use in refrigerators, freezers, ... racks. Four vibrant colors allow for color coding to ... liquid nitrogen drainage or promote cool air circulation. Supplied ... holds 100 tubes. Box dimensions: 13 x ...
RABBIT ANTI BACTERIAL HISTIDASE...
REGULATED IN DEVELOPMENT AND DNA DAMAGE RESPONSES 1,HIF-1 responsive RTP801...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
Biology Products: